(AOF) – Deinove has announced that it has received a favorable opinion from the DSMB and is continuing the Phase II trial evaluating DNV3837 in Clostridioides difficile infections. The company posted cash of €3.8 million as of December 31, 2021, compared to €2.9 million as of December 31, 2020. In September 2021, it set up a new convertible bond contract (OC ). On January 26, 2022, the third CB tranche was subscribed by ESGO Fund, for an amount of 500,000 euros.
The biotechnology company recorded a net loss, group share, 2021 of 7 million euros compared to -7.3 million euros in 2020, mainly thanks to the reduction in operating expenses.
AOF – LEARN MORE